Advertisement

Inflammation Research

, Volume 49, Issue 5, pp 240–246 | Cite as

Phenotypic variation in mast cell responsiveness to the inhibitory action of nitric oxide

  • R.D. Koranteng
  • R.J. Dearman
  • I. Kimber
  • J.W. Coleman

Abstract.

Objective and design: The aim of this study was to investigate the possible phenotypic variations between mast cells in terms of their responsiveness to the inhibitory actions of nitric oxide.¶Materials: Unfractionated mouse peritoneal cells, purified rat peritoneal mast cells, mouse bone marrow-derived mast cells of the Cl.MC/C57.1 line (cultured mouse mast cells, CMMC) and rat basophilic leukemia cells of the RBL-2H3 line were used.¶Methods: Mast cells were cultured with interferon-γ (IFN-γ)-stimulated mouse peritoneal cells as a source of nitric oxide, or with the nitric oxide donor S-nitrosoglutathione (SNOG). After 24 h culture, the mast cells were challenged with anti-IgE, antigen, or calcium ionophore A23187, and degranulation measured as release of [3H]serotonin.¶Results: Addition of IFN-γ to mouse peritoneal cells led to nitric oxide synthesis and this was associated with decreased IgE-mediated mast cell degranulation. IFN-γ did not induce nitric oxide production by CMMC and degranulation of CMMC was not inhibited by nitric oxide generated by co-cultured IFN-γ-activated peritoneal cells. The nitric oxide donor SNOG inhibited degranulation of purified rat peritoneal mast cells, but not RBL-2H3 cells, stimulated by either IgE cross-linking or calcium ionophore.¶Conclusions: The inhibitory effects of nitric oxide on mast cell degranulation are variable and selective for phenotype. Such phenotypic differences may reflect important variations in regulation of mast cell function.

Key words: Cell lines — Mast cell — Nitric oxide — Serotonin release 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, 2000

Authors and Affiliations

  • R.D. Koranteng
    • 1
  • R.J. Dearman
    • 2
  • I. Kimber
    • 2
  • J.W. Coleman
    • 1
  1. 1. Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE, United Kingdom, Fax: +44 151 794 5540, e-mail: coleman@liverpool.ac.ukUK
  2. 2.AstraZeneca Central Toxicology Laboratory, Macclesfield, Cheshire, SK10 4TJ, United KingdomUK

Personalised recommendations